Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats

European Neuropsychopharmacology

Volumn 14, Issue 2, 2004, Pages 127-133

  Perry, J C ^a   Vital, M A B F ^a   Frussa Filho, R ^b   Tufik, S ^b   Palermo Neto, J ^c  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dopaminergic supersensitivity; GM1; Haloperidol; Monosialoganglioside; Tardive dyskinesia

Indexed keywords

APOMORPHINE; HALOPERIDOL; MONOSIALOGANGLIOSIDE; SPHINGOLIPID ACTIVATOR PROTEIN 1; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GANGLIOSIDE GM1;

ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG POTENTIATION; DRUG WITHDRAWAL; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; STEREOTYPY; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG INTERACTION; IMMOBILIZATION; TIME; WISTAR RAT; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; G(M1) GANGLIOSIDE; HALOPERIDOL; IMMOBILIZATION; LOCOMOTION; MALE; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0842285442     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00074-9     Document Type: Article

References (37)

1. Abílio V.C., Freitas F.M., Dolnikoff M.S., Castrucci A.M.L., Frussa-Filho R. Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. Biol. Psychiat. 45:1999;1622-1629.
2. Agnati L.F., Fuxe K., Benfenati F., Battistini N., Zini I., Toffano G. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment. Neurosci. Lett. 40:1983;293-297.
3. 1 ganglioside therapy in acute ischemic stroke. Cerebrovasc. Dis. 2:1992;163-168.
4. Bellot R.G., Camarini R., Vital M.A.B.F., Palermo-Neto J., Leyton V., Frussa-Filho R. Monosialoganglioside attenuates the excitatory and behavioural sensitization effects of ethanol. Eur. J. Pharmacol. 313:(3):1996;175-179.
5. Bellot R.G., Vital M.A.B.F., Palermo-Neto J., Frussa-Filho R. Repeated monosialoganglioside administration attenuates behavioural sensitization to amphetamine. Brain Res. 747:(1):1997;169-172.
6. Bernardi M.M., Palermo-Neto J. Effects of abrupt and gradual withdrawal from long-term haloperidol treatment on open-field behavior of rats. Psychopharmacology. 65:1979;247-250.
7. Bernardi M.M., De Souza H., Palermo-Neto J. Effects of single and long-term haloperidol administration on open-field behavior of rats. Psychopharmacology. 73:1981;171-175.
8. Broadhurst P.L. Experiments in psychogenetics. Eisenk H.J. Experiments in Personality. 1960;52-71 Routledge and Kegan Paul, London.
9. Cunha G.M.A., Moraes R.A., Moraes G.A., França-Júnior M.C., Moraes M.O., Viana G.S.B. Nerve growth factor, ganglioside and vitamin E reverse glutamate cytotoxicity in hippocampal cells. Eur. J. Pharmacol. 367:1999;107-112.
10. Dawson T.M., Hung K., Dawson V.L., Steiner J.P., Snyder S.H. Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann. Neurol. 37:1995;115-118.
11. Ferrari G., Anderson G.L., Stephens R.M., Kaplan D.R., Greene L.A. Prevention of apoptotic neuronal death by GM1 ganglioside: involvement of Trk neurotrophin receptors. J. Biol. Chem. 270:1995;3074-3080.
12. Fighera M.R., Bonini J.S., Oliveira T.G., Frussa-Filho R., Rocha J.B.T., Dutra-Filho C.S., Rubin M.A., Mello C.F. GM1 ganglioside attenuates convulsion and thiobarbituric acid reactive substances production induced by intrastriatal injection of methylmalonic acid. Int. J. Biochem. Cell Biol. 1415:2002;1-9.
13. 1: effect of lipid moiety on choleragen action. J. Biol. Chem. 255:1980;7657-7664.
14. Fishman P.H. Role of membrane gangliosides in the binding and action of bacterial toxins. J. Membrane Biol. 69:1982;85-97.
15. Fuxe K., Agnati L.F., Benfenati F., Zini I., Gavioli G., Toffano G. New evidence for the morphofunctional recovery of striatal function by ganglioside GM1 treatment following a partial hemitransection of rats. Studies on dopamine neurons and protein phosphorylation. Tettamanti G., Ledeen R.W., Sandhoff K., Nagai Y., Toffano G. Gangliosides and Neuronal Plasticity. 1986;347-363 Liviana Press, Padova, Italy.
16. 1 ganglioside. New Engl. J. Med. 324:1991;1829-1838.
17. Glasier M.M., Janis S., Gonçalves M.I., Stein D.G. GM1 produces attenuation of short-term memory deficits in Hebb-Williams maze performance after unilateral entorhinal cortex lesions. Physiol. Behav. 66:(3):1999;441-446.
18. Goettl V.M., Wemlinger T.A., Duchemin A.M., Neff N.H., Hadjiconstantinou M. GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats. Neuroscience. 92:(3):1999;991-1000.
19. Goldering J.R., Otis L.C., Yu R.K., Delorenzo R.J. Calcium/ganglioside- dependent protein kinase activity in rat brain membranes. J. Neurochem. 44:1985;1229-1234.
20. Johnson N., Leone F. Statistic and experimental design. Engineering and Physical Sciences. 1974;Wiley, New York.
21. 1 ganglioside. J. Neurochem. 37:1981;350-357.
22. 1 ganglioside attenuates changes in neurochemistry and behaviour caused by repeated haloperidol administration. Neurodegeneration. 3:1994;135-140.
23. Palermo-Neto J. Supersensitivity, drug withdrawal, and open-field behavior. Psychopharmacol. Bull. 18:1982;11-12.
24. Palermo-Neto J., Frussa-Filho R. Behavioural models of tardive dyskinesia in rodents: a chronological overview. Bolis C.L., Pani L., Licinio J. Dopaminergic System: Its Evolution From Biology To Clinical Aspects. 2000;61-81 Lippincott Williams Wilkins Healthcare, Philadelphia.
25. Papo I., Benedetti A., Carteri A., Meril G.A., Migliore A., Mingrino S., Cornelli U., Bruno R. Monosialoganglioside in subarachnoid hemorrhage. Stroke. 22:1991;22-26.
26. Partington C.R., Daly J.W. Effect of gangliosides on adenylate cyclase activity in rat cerebral cortical membranes. Mol. Pharmacol. 15:1979;484-491.
27. Queiroz C.M.T., Frussa-Filho R. Effects of buspirone on dopaminergic supersensitivity. Life Sci. 61:1997;371-382.
28. Ramirez J.J., Sabel B.A. Toward a unified theory of ganglioside-mediated functional restoration after brain injury: lesion size, not lesion site, is the primary factor determining efficacy. Acta Neurobiol. Exp. 50:1990;415-438.
29. Ryu B.R., Choi D.W., Hartley D.M., Costa E., Jou I., Gwag B.J. Attenuation of cortical neuronal apoptosis by gangliosides. J. Pharmacol. Exp. Ther. 290:1999;811-816.
30. 1 ganglioside in the treatment of Parkinson's disease: an open pilot study of safety and efficacy. Neurology. 45:1995;1149-1154.
31. Schröder U., Schröder H., Augustin W., Sabel B.A. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding. J. Pharmacol. Exp. Ther. 271:1994;1193-1196.
32. 1. Pharmacol. Biochem. Behav. 58:1997;903-907.
33. Setler P., Sarau H., McKenzie G. Differential attenuation of some effects of haloperidol in rats given scopolamine. Eur. J. Pharmacol. 39:1976;117-126.
34. Siegel S. Nonparametric Statistics for the Behavioral Sciences. 1956;117-127 McGraw-Hill, New York.
35. 1 ganglioside with crude rat brain neuronal membranes. J. Neurochem. 35:1980;861-866.
36. 1 on dopaminergic supersensitivity. Life Sci. 56:1995;2299-2307.
37. 2 receptor binding and dopamine turnover. Life Sci. 62:1998;1161-1169.